Kairos Pharma Includes Huntsman Cancer Institute in Phase 2 Trial for ENV105

Kairos Pharma Ltd., a biopharmaceutical firm in the clinical-stage space, has expanded its Phase 2 clinical trials for ENV105 to include the Huntsman Cancer Institute located in Salt Lake City, Utah. This expansion is aimed at treating patients with castrate-resistant prostate cancer. The ongoing clinical trial is testing the efficacy of ENV105 when used in combination with apalutamide, compared to apalutamide alone. This initiative is backed by both Kairos Pharma and a grant from the National Cancer Institute (NCI).

Dr. Neil Bhowmick, the Chief Scientific Officer of Kairos Pharma, emphasized the importance of adding Huntsman Cancer Institute to their list of investigational sites. According to Dr. Bhowmick, incorporating multiple sites enables the company to assess ENV105 across a diverse patient demographic. This broad approach facilitates the identification of blood markers that could potentially predict which patients would benefit most from the treatment. The inclusion of a prestigious institution like Huntsman is expected to enhance the credibility of the study within the medical community.

Dr. John Yu, CEO of Kairos Pharma, expressed that this development marks a significant milestone for the company. The collaboration with Huntsman Cancer Institute serves as further validation of the scientific approach underpinning ENV105. The trial aims to tackle the resistance that typically develops in prostate cancer patients undergoing hormone therapy. Dr. Yu pointed out that Huntsman Cancer Center is a top-tier research institution, and the company looks forward to continuing its partnership with them.

Kairos Pharma Ltd., headquartered in Los Angeles, California, is a leader in cancer therapeutics, focusing on overcoming drug resistance and immune suppression through structural biology. Their flagship product, ENV105, is an antibody that targets CD105. This protein is recognized as a major contributor to the resistance against various cancer treatments. Increased levels of CD105 in response to standard therapies often lead to treatment resistance and disease recurrence. ENV105 aims to counteract this resistance by targeting CD105, thereby restoring the effectiveness of conventional therapies across multiple cancer types. Currently, ENV105 is undergoing a Phase 2 clinical trial for castrate-resistant prostate cancer, alongside a Phase 1 trial for lung cancer, both addressing substantial unmet medical needs.

By expanding their clinical trials and collaborating with prominent research institutions, Kairos Pharma is working towards more effective cancer treatments. Their innovative approach in targeting specific proteins involved in cancer treatment resistance underscores their commitment to advancing oncological therapeutics. This strategy not only aims to enhance the efficacy of existing treatments but also seeks to address significant gaps in current cancer care. As the trials progress, the company continues to focus on the potential benefits that ENV105 could offer to patients who have developed resistance to standard cancer therapies.